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Relationship between supersaturation and crystal inhibition in hyper-
calciuric rats. Calcium oxalate (CaOx) and calcium phosphate (CaP)
crystals do not precipitate in large amounts in normal urine despite
considerable supersaturation (SS), partly because urine inhibits crystal
nucleation, aggregation, and growth. In normal rats and rats bred for
hypercalciuria (GHS), we varied SS by varying calcium intake to test the
hypothesis that increased SS might deplete inhibitors and reduce inhibi-
tion of crystal formation. In normal rats when compared to a low calcium
diet (0.02% Ca), a high calcium diet (1.2% Ca) raised the SS of CaOx from
0.8 to 8.2. The high calcium diet also raised the upper limit of metastability
(ULM) of CaOx (the SS at which crystals form in urine) from 11.8 to 36.
In GHS rats, diet change altered CaOx SS from 1.5 to 12, and ULM from
17 to 50 (all differences, P < 0.001). Because ULM rose with SS, the
increased SS had little potential to increase CaOx stone risk. For CaP,
however, SS rose from 0.6 to 2.4 and 1.1 to 8 in normal and GHS rats (P <
0.001 for both), respectively, whereas ULM for CaP did not increase
significantly (8 vs. 7 and 7 vs. 11; P = NS, both changes). Therefore, CaP
SS rose close to the ULM, posing a high stone risk. The stones formed by
these rats are composed of CaP. Increasing CaOx SS by diet raises ULM
for CaOx thereby offsetting the risk of CaOx stones in rats.
It is widely accepted that hypercalciuria causes human stone
disease by increasing urine supersaturation with respect to stone
forming salts such as calcium oxalate (CaOx) and calcium phos-
phate species (CaP) [1]. In order to analyze the processes of stone
formation by hypercalciuria, and to understand the pathogenesis
of hypercalciuria, we bred rats for 39 generations to produce a
strain that exhibits marked hypercalciuria [2—4]. Elsewhere we
have shown that the hypercalciuria produces abnormally high
supersaturation with respect to both CaOx and CaP [5] and that
all of these rats produce stones [6]. Calcium phosphate supersat-
uration exceeds normal by a greater margin than does CaOx
supersaturation, and the actual stones formed by the rats are
composed exclusively of calcium phosphate salts [6].
Supersaturation alone does not determine crystallization. In
urine, the upper limit of metastability is higher than in simple
buffered solutions [7], presumably because urine contains mate-
rials that inhibit formation of nuclei [8, 9]. A reduction of the
upper limit of metastability could foster stones by permitting
crystallization at a lower supersaturation. In addition, urine
contains potent inhibitors of the growth [10, 11] and aggregation
[12, 13] of any CaOx and CaP nuclei that do form. Quite possibly,
supersaturation could lead to nucleation, and new crystals could
adsorb the urine materials that normally raise the upper limit of
metastability. Exhaustion of inhibitors could lead to a cycle of
reduced upper limit of metastability and increased rate of nucle-
ation, as well as more rapid growth and aggregation of crystals.
Alternatively, stone formation could be caused by abnormal
amounts or types of inhibitors, leading to a sustained reduction of
the upper limit of metastability, and reduced inhibition of crystal
growth and aggregation.
To explore mechanisms of stone production, we have measured
upper limits of metastability and supersaturation with respect to
CaOx and brushite [14], a calcium phosphate phase that can
convert to apatite [151. In addition, we have studied the urine
from the rats with respect to inhibitors of calcium oxalate
monohydrate crystal growth [16] and aggregation [12]. Both
control and genetic hypercalciuric stone forming (GHS) rats were
studied under varying dietary conditions [17] in order to define
the relationship between supersaturation and urinary inhibitory
activity.
Methods
Animals and diets
Establishment of hypercalciuric rats. Initially 20 male and 20
female adult Sprague-Dawley rats (Charles River Laboratories,
Kingston, NY, USA) were screened for hypercalciuria. The rats
were placed in individual metabolic cages and allowed five days to
adjust to the cage and diet. The animals were fed a diet containing
1.2% calcium, 0.90% phosphorous, 0.24% magnesium, 0.40%
sodium, and 0.43% potassium and 2.2 IU vitamin D3/gram of
food. The rats with the greatest urine calcium excretion were used
to breed the next generation. A similar protocol was used to select
the most hypercalciuric rats for inbreeding of subsequent gener-
ations [2].
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Thirty-ninth generation female GHS rats were kept in the
metabolic cages and some (N 8) were continued on the same
diet (High Ca) while others (N 8) were switched to a matched
low calcium diet, which contained 0.02% calcium, 0.45% phos-
phorus, 0.24% magnesium, 0.40% sodium and 0.43% potassium
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and 2.2 IU vitamin D3 gram of food (Low Ca). Control rats were
housed and fed either High Ca or Low Ca identically. Rats were
pair fed; on each diet each GHS rat was offered unlimited diet and
the paired control rat was given the same amount of food on the
next day. Deionized, distilled water was provided ad libitum. The
control rats were the same gender, the same strain (Sprague-
Dawley) obtained from the same supplier and were studied
concurrently at the same age and weight as the GHS rats. After
two weeks of pair feeding to establish a steady state, we began to
collect 24 hours urines. The initial urine collection was in 0.25 ml
of 12 N HCI for oxalate and citrate determinations and the
subsequent collections were in thymol for all other values. Col-
lections, in thymol, were continued for 14 days to achieve a
minimum of 100 ml of urine for each rat. Every day urine was
collected, volume measured and transferred to a refrigerated vial
prior to analysis. The urine from each rat was pooled to have
sufficient material for all assays and all urines were analyzed
concurrently.
Urine chemistries
Urine pH was measured by glass electrode (Beckman Instru-
ments, Brea, CA, USA). Sodium, potassium, chloride, calcium,
phosphorous, magnesium, uric acid, ammonia, and creatinine
concentrations were measured by standard laboratory techniques
using a Beckman Synchron CX5 (Beckman Instruments). Oxalate
and citrate were measured by ion chromatography (Dionex Corp.
Sunnyvale CA, USA). Sulfate was determined by barium precip-
itation. Urine supersaturation of calcium oxalate and calcium
phosphate was calculated using the iterative computer program
EQUIL, which solves simultaneously for all known ion interac-
tions [18]. The results are expressed as relative supersaturation
ratio which is the ratio of the calculated concentration of the salt
to the solubility of the salt.
Non-dialyzable urine protein
Urine samples were dialyzed against water with 0.02% sodium
azide for three days with three changes of water. Non-dialyzable
urine protein was measured using ninhydrin. An aliquot of urine
was hydrolyzed in 0.5 ml of 1 N NaOH for 16 hours. After
hydrolysis, pH was adjusted to 5.7 with 0.5 ml of 7.5% acetic acid.
Ninhydrin was added and the mixture boiled for fifteen minutes.
Absorbance was measured at 570 nm and protein concentration
determined by comparison to a standard curve made with samples
of bovine serum albumin of known concentration.
Upper limit of metastability
A modification of the method described by Nicar, Hill and Pak
[14] was used to determine the upper limit of metastability (ULM)
of calcium oxalate and calcium phosphate in the rat urine. Pooled
urine from each rat was centrifuged for 30 minutes at 3000 RPM
to remove debris. Urine pH was adjusted to 6.4 by addition of HCI
or NaOH as required. Two ml of each urine sample was placed
into each of 13 tubes, and sodium azide was added to each tube,
final concentration of 0.02%, to prevent bacterial growth. The
tubes were placed in a water bath at 37°C, and were magnetically
stirred. To initiate calcium oxalate precipitation, increasing
amounts of sodium oxalate were added to each set of tubes, one
tube had no oxalate added to serve as a blank. The pH was
checked hourly during the three hour incubation and acid or alkali
added as needed to maintain pH at 6.4. After three hours the
samples were checked for visible precipitation, and the lowest
amount of oxalate added that initiated crystallization was consid-
ered the end point. The supersaturation at the point of precipi-
tation was calculated using EQUIL, assuming all ion concentra-
tions were unchanged except for oxalate, which was taken as the
initial measured oxalate concentration plus the amount added.
Calcium phosphate upper limit of metastability was determined in
the same fashion, except calcium chloride was added to the urine
samples to precipitate brushite [7].
Crystal growth inhibition
Calcium oxalate monohydrate (COM) crystal seed slurries (0.8
mg/mi) were prepared by the addition of 8 mg of COM crystal
(average diameter 2 to 5 m) to 10 ml of 10 mrvi Tris buffer, pH
7.2. The slurry was mixed with a magnetic stirrer overnight at 1100
RPM. The seed slurry was added to 2 ml of a metastable calcium
oxalate solution consisting of 0.5 m Ca, 0.5 mM oxalate, 90 mM
NaC1, 10 mivi Tris, pH 7.2, contained in a quartz cuvette, 37°C, and
magnetically stirred at 1100 RPM. Oxalate consumption was
initiated by addition of seed crystals and was monitored for 400
seconds with a continuous recording spectrophotometer at 214
nm. Data were collected using a Lambda 7 spectrophotometer
(Perkin Elmer Corp., Norwalk, CT, USA) interfaced to an Apple
II computer by an Adalab data acquisition system (Interactive
Microware, State College, PA, USA). The rate of oxalate con-
sumption follows second order kinetics, and from the integrated
rate equation the velocity of the reaction was derived [16]. The
assay was run with and without the dialyzed rat urine protein in an
alternating fashion such that each urine sample was sandwiched
by two control measurements. Duplicates were run for each rat
urine sample. Since urine protein excretion rates were signifi-
cantly different between hypercalciuric and control rats (Table 2),
we added 0.06% of the dialyzed urine protein excreted over the
two week collection period. We chose to add urine protein as a
percent of excretion rate rather than at a fixed concentration,
since it was assumed that crystal inhibitors would make up a
smaller fraction of protein excreted from the hypercalciuric rat if
they had a nonspecific proteinuria from interstitial nephritis. The
fraction of protein added, 0.06%, was based on previous experi-
ence showing this amount of protein would give inhibition results
centered in the dynamic range of the assay. Results for the protein
samples are expressed as a percent of the reaction velocity of the
controls, such that greater inhibition will result in smaller reaction
velocities and a lower percent of control.
Aggregation inhibition
Calcium oxalate monohydrate crystal slurries 0.8 mg/mI (aver-
age crystal diameter of 2 to 5 .tm) were prepared in 10 mivi
acetate, pH 5.7, and equilibrated overnight at 37°C, magnetically
stirred at 1,100 RPM. The crystals and solution came to equilib-
rium so crystals no longer dissolved or grew. The slurry was then
pipetted into multiple tubes, each used for a single assay. Rat
urine protein samples were added to the stirred slurries 30
minutes prior to assay. A 2 ml aliquot of the crystal slurry was
transferred to a quartz cuvette maintained at 37°C, and was
constantly monitored at 620 nm. In this system 0D620 was
proportional to the mass of crystal per unit volume [19]. The
slurry was initially stirred at 1,100 RPM to obtain a stable
baseline, and then crystal aggregation was induced by slow stirring
at 500 RPM for 170 seconds. Stirring was stopped and particle
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Rat diet
Control GHS
Low Ca High Ca Low Ca High Ca
Urine measurement
Calcium 5.4 0.23 16 2 19 1)' 158 12"
Citrate 122 17 566 6I 287 28" 934 126
Oxalate 5.7 0.5 11 1.2 8.9 1.0" 10.4 1.2
Phosphorus
Magnesium
790 26
139 5
137 12k'60 5 956 60" 233 28"168 12 102 9'
pH 5.59 0.04 7.25 0.19a 5.84 008" 6.96 0.24'
Sulfate 12 1 10 P 15 1h 12 1
Ammonium 15 1 12 2 23 2" 23 6
Sodium 31 1 32 2 36 2" 38 2
Potassium 17 1 17 1 19 1 19 I
Uric acid 21 1 20 2 27 3 31 4"
Volume 128 13 148 19 318 43" 370 57"
Abbreviations are: Control, normal Sprague-Dawley rats; GHS, genetic
hypercalciuric stone forming rats; Low Ca, diet of 0.2% calcium, 0.45%
phosphorus; High Ca, diet of 1.2% calcium, 0.90% phosphorus. Calcium,
citrate, oxalate, phosphorous, magnesium, and uric acid expressed as
mg/14 day collection. Sulfate, ammonium, sodium, and potassium ex-
pressed as mmol/14 day collection. Volume in ml is per 14 day collection.
a Differs from Low Ca diet, same type of rat, P < 0.05
bDiffers from same diet, control rat, P < 0.05
sedimentation monitored. The rate of fall in 0D620, measured as
the slope of the straight portion of the plot of OD versus time,
reflected the average particle size and was taken as a measure of
aggregation [19]. The assay was run with and without the dialyzed
urine proteins added to the slurry in an alternating fashion. Urine
protein was added as 0.02% of the dialyzed urine protein excreted
during the two-week collection period. The fraction of protein
added, 0.02%, was based on previous experience showing that this
amount of protein would give inhibition results centered in the
dynamic range of the assay. Duplicates were run for each urine
sample. Results for the protein samples are expressed as a percent
of the sedimentation rate of the controls.
Statistical analysis
All results are expressed as means standard error. Analysis of
covariance was used to determine if crystal inhibition was different
between groups when allowing for the variable amount of protein
added to each assay. Density contour plots were produced using
the Epanechnikov kernel [20]. All statistical calculations were
performed using Systat software (Systat Inc. Evanston, IL, USA).
Results
Compared to rats fed the low calcium diet, urine calcium
excretion rate was increased in both control and GHS rats on the
high calcium diet and was higher in the GHS than in the control
rats on each diet (Table 1). Urine citrate and pH were lower
during the low calcium diet in both control and GHS rats; citrate
was higher in the GHS compared to control rats for both diets.
Phosphorus was markedly higher on the low calcium diet, and
higher in the GHS than in the control rats.
The net effect of all the urine compositional changes on stone
forming risk could be expressed as supersaturation of the perti-
nent stone forming salts. On a low calcium diet, control rats had
low CaOx and CaP supersaturation values while the GHS rats
showed higher values (Figs. 1 and 2, and Table 2). A high calcium
diet increased supersaturation for both phases (Figs. 1 and 2), but
Fig. 1. Relationship between calcium oxalate (Ca Ox) upper limit of meta-
stability and supersaturation. Compared to the low calcium diet (circles) the
CaOx supersaturation (SS) (x axis) increases with the high calcium diet
(triangles) in both control (open symbols) and GHS (closed symbols) rats.
The nucleation threshold (y axis) rises with SS. The logarithmic line of
identity is shown for reference.
was more marked in the GHS rats. The upper limit of CaOx
metastability was higher for GHS than control rats on the high
calcium diet (Table 2, and Figs. 1 and 2) and increased in both rats
with high calcium diets. As a result, the distance between the
upper limit of metastability and the prevailing supersaturation was
constant throughout the range measured. For CaP, however, this
was not the case as the upper limit did not rise smoothly with
supersaturation, and the distance between the limit and the
prevailing supersaturation fell with a higher supersaturation. In
other words, CaP SS came near to the upper limits of metastabil-
ity, posing a high risk for crystallization, whereas for CaOx SS
increases were matched by corresponding increases in the upper
limit.
GHS rats excreted more protein than control rats (59 vs. 91
mgIl4 days, P < 0.001). A change in diet had no influence on
protein excretion (Table 2). A fixed proportion of the excreted
protein was added to each assay, and therefore more protein was
added to the GHS flasks than control (35 vs. 54 mg for growth, 12
vs. 18mg for aggregation, control vs. GHS, P < 0.001 for both). By
simple 1-tests, without allowance for the higher protein additions
for GHS rats, the low calcium diet GHS rats showed a significant
reduction of growth inhibition versus the low calcium diet control
rats. There was no difference between the rats fed a high calcium
diet (Table 2). When the amounts of protein added to each assay
were taken into consideration as independent variables by analysis
of covariance, CaOx growth inhibition was lower in GHS than
control rats (Fig. 3) for both diets (adjusted means SE were 44
5 vs. 63 5, control vs. GHS, P = 0.031). For aggregation there
were no significant differences between GHS rats and controls by
a simple t-test. When adjusted for the protein added to the assay
Table 1. Urinary excretion of pertinent ions
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Fig. 2. Relationship between calcium phosphate (CaP) upper limit of meta-
stability and supersaturation. Compared to the low calcium diet (circles) the
CaP SS (x axis) increases with the high calcium diet (triangles) in control
(open symbols) and GHS (closed symbols) rats. The nucleation threshold
(y axis) does not rise with SS; as a result, points become progressively
displaced toward the logarithmic line of identity.
Rat diet
Control GHS
Low Ca High Ca Low Ca High Ca
Urine measurement
SS CaOx
ULM CaOx
SS CaP
ULM CaP
Growth
Aggregation
Protein
0.8 0.112 1
0.6 0.1
8.0 142 362 262 7
8.2 iSa36 4
2.4 0.4
7.5 1.254 863 355 7
1.5 03b
17 2
1.1 02b
7.2 0.6
61 4b
66 4
91 9b
12 250 3'
8 1a,b
11 ia
56 10
81 1390 9'
Abbreviations are: Control, normal Sprague-Dawley rats; GHS, genetic
hypercalciuric stone forming rats; Low Ca, diet of 0.2% calcium, 0.45%
phosphorus); High Ca, diet of 1.2% calcium, 0.90% phosphorus); SS,
supersaturation (unitless); CaOx calcium oxalate, CaP calcium phosphate;
ULM, upper limit of metastability (unitless); Growth, CaOx crystal growth
expressed as % of control; Aggregation, aggregation of CaOx crystals
expressed as % of control; Protein, urine protein excretion in mgIl4 days
Differs from Low Ca diet, same type of rat, P < 0.05b Differs from same diet, control, P < 0.05
by analysis of covariance, aggregation inhibition was reduced in
the OHS rat (adjusted means SE were 59 5 vs. 78 5, control
vs. GHS, P = 0.035) and diet change had no influence (Fig. 4).
Discussion
Quite unexpectedly, we have found that deliberate variation of
CaOx supersaturation by diet change causes a corresponding and
parallel change in the ULM. As a result, the urine apparently
holds a higher concentration of CaOx when necessary. How this
variation is achieved is not clear. Since the higher ULM in urine
than in simple buffered solution appears due to nondialyzable
0
0 20 40 60 80 100
Protein, jig/assay
Fig. 3. Inhibition of calcium oxalate monohydrate (COM) crystal growth by
urine proteins. The inhibitory activity per microgram of protein per assay is
higher in the control rat (open symbols) than in the GHS rat (P = 0.031)
as can be seen by the general shift of points to the right and below the
GHS rats (closed symbols). A density contour plot for the control rat
values is provided to highlight the difference between the groups; numbers
on plotted rings indicate density of data in arbitrary units. Few GHS points
are contained in the control contour regions (see Results).
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Table 2. Supersaturations and inhibitions
molecules [21], one must presume that diet change has altered the
amounts or compositions of some critical components of nucle-
ation inhibition. Uropontin [10], nephrocalcin [9] and glycosami-
noglycans [22] are known to inhibit nucleation of CaOx, and are
in urine. Tamm Horsfall protein [13], an inhibitor of aggregation,
does not inhibit nucleation. Our present work indicates a need to
explore possible roles for these substances, and perhaps others,
such as uronic acid rich proteins [23], in altering the ULM.
Also unclear is the mechanism controlling inhibitory activity.
Whether urine calcium concentration, supersaturation, or intesti-
nal calcium transport are sensed with diet change and alter
inhibitor level is unknown. Quite possibly, parathyroid hormone,
or calcitriol, whose levels change with altered calcium intake, play
a role [17].
For calcium phosphate, we found no effects of diet change on
the ULM. As a result, brushite supersaturation rose with high
calcium diet very near to the ULM, posing a theoretical risk of
CaP crystallization. Surprisingly, citrate, a known inhibitor of CaP
crystallization, increases on the high calcium diet despite no
change in the ULM. Presumably other unmeasured inhibitors of
calcium phosphate have been reduced or the activity of citrate as
an inhibitor has been reduced at the higher urine pH [24] resulting
in no net change in CaP inhibition. In the GHS rats, stones are
entirely CaP in composition. This suggests that the closeness of
the ULM and supersaturation may indeed be a main mechanism
controlling stone production. On the other hand, the large
distance between supersaturation and ULM for CaOx could well
644 Asplin et al: C,ystal inhibition in rats
Protein, gig/assay
Fig. 4. Inhibition of CaOx monohydrate (COM) ctystal aggregation by urine
proteins. The inhibitory activity per microgram of protein per assay is
higher in the control rat (open symbols) than in the GHS rat (P = 0.035)
as can be seen by the general shift of points to the right of the GHS rats
(closed symbols). Density contour plot as in Figure 3 (see Results).
be the reason no stones contain any CaOx despite extreme
hypercalciuria and high SS for CaOx.
Whereas CaOx nucleation seemed progressively inhibited by
high calcium intake, and was high in the GHS rats, CaOx crystal
growth inhibition by dialyzed urine proteins was reduced com-
pared to control rats. This reduction was not so much absolute as
relative to the amount of inhibition produced by a given concen-
tration of urine protein. GHS rats excreted more protein than
control rats, but their urine protein inhibited less effectively per
milligram added to our assay. As a result, the net inhibition by
urine proteins was not remarkably below normal, when protein
was added to our assays as a constant proportion of the 14 days
excretion. Aggregation inhibition was also reduced per milligram
of protein, but probably not lower in whole urine, because
proportional addition to our assays resulted in approximately
equal total inhibitions by UI-IS rat and control urine proteins.
Nevertheless, per milligram of protein added, proteins from GHS
rats inhibited aggregation less well than control rats. The lower
specific activity of GE-IS urine protein as an inhibitor of growth
and aggregation is best explained by postulating that the GHS rats
excrete more proteins that do not inhibit than control rats excrete.
We do not know which proteins account for the higher protein
excretion rate in the GHS rat.
Consistent with our previous study, in spite of a reduction in
phosphate content in the low calcium diet, urinary phosphorous
was higher in rats fed this diet [5]. Increased urinary phosphorus
with the low calcium diet was almost certainly due to less calcium
phosphorus complexation in the intestine resulting in greater
phosphorus absorption and excretion. We have also previously
shown that increasing dietary calcium led to an increase in urinary
pH and citrate excretion [5]. This appears due to the increased
base content in the high calcium diet leading to increased urinary
pH and citrate [25, 26].
Overall, stone production by GHS rats seems to be controlled
by a complex system that protects against CaOx nucleation but not
against CaP nucleation. As a result of hypercalciuria, CaP SS rises
without a corresponding increase in the CaP ULM, and this is
associated with, and possibly directly causal of CaP stones and
nephrocalcinosis. The rise in CaOx ULM, however, offsets the rise
in supersaturation with respect to CaOx with high calcium intake,
and this may account for the lack of CaOx stones in these rats.
Whether these results apply to human nephrolithiasis, and the
mechanisms responsible, remain to be elucidated.
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